Technology Bundle ID
TAB-3550

Small Molecule BET Bromodomain Inhibitors for the Treatment of Cancer and Inflammatory Diseases

Applications
Linked ID
E-118-2019-0
Lead Inventors
Makoto Yoshioka (ConverGene, LLC)
Co-Inventors
Shyh Yang (NCATS)
ICs
This technology includes a new chemical series of substituted bicyclic heteroaryl small molecules as potent bromodomain-containing protein BRD4 inhibitors used for the treatment of cancer and inflammatory diseases. The optimization led to compounds with good potency in enzymatic assay (
Commercial Applications
BRD4 has been identified as an important target for a number of potential indications, particularly cancer and inflammatory diseases, as well as diabetes and acute heart failure.
Competitive Advantages
These compounds have novel composition and better drug-like properties, and also have the potential to be used for a variety of indications.

Request More Info

Licensing Contact: